Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04226898 · ClinicalTrials.gov registry record · Phase 2
Synbiotic Compound to Reduce Symptoms of Schizophrenia
A Phase 2 study, sponsored by Sheppard Pratt Health System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT04226898 is a Phase 2 study that is actively recruiting participants, run by Sheppard Pratt Health System. The registered enrollment target is 68 participants.
The verdict
NCT04226898, a Phase 2 study, is actively recruiting participants, sponsored by Sheppard Pratt Health System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if taking a synbiotic supplement versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
Interventions
- BIOLOGICAL Synbiotic Supplement
- BIOLOGICAL Inert Compound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-02-21 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04226898
The ClinicalTrials.gov registry entry for NCT04226898 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sheppard Pratt Health System, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Synbiotic Supplement is the first listed.
NCT04226898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04226898 about?
NCT04226898 is a clinical study titled "Synbiotic Compound to Reduce Symptoms of Schizophrenia". The purpose of this study is to determine if taking a synbiotic supplement versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.
What is the current status of trial NCT04226898?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2022-02-21. Estimated completion is 2027-12.
What interventions are being tested in trial NCT04226898?
The interventions under investigation include: Synbiotic Supplement (BIOLOGICAL), Inert Compound (BIOLOGICAL).
Who is sponsoring clinical trial NCT04226898?
This trial is sponsored by Sheppard Pratt Health System, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.